Upcoming events
2021
November
11
December
16
KOL webinar on C21 for the treatment of IPF
Hosting the medical doctors and IPF experts Prof. Toby Maher and Prof. Joanna Porter.
Previous presentations
Redeye Growth Day, June 3 2021
CFO, Hans Jeppsson presented Vicore Pharma at Redeye Growth Day on June 3, 2021.
Corporate presentation, May 11 2021
CEO, Carl-Johan Dalsgaard gives an update on Vicore's operations for the virtual AGM.
DTx webinar, May 4 2021
Presentation on the digital therapeutic (DTx) program.
KOL webinar on COVID-19, April 28 2021
Presentation by KOL Professor Maureen Horton, M.D., Johns Hopkins University School of Medicine on the current treatment landscape and unmet medical needs in treating patients with COVID-19. Update on the results from Vicore's phase II study in COVID-19 and the coming phase III pivotal study.
Redeye interview, March 30 2021
Interview with CEO Carl-Johan Dalsgaard on the results from the phase II mechanistic study in systemic sclerosis (in Swedish).
Pareto interview, March 22 2021
Interview with CEO, Carl-Johan Dalsgaard on the results from the phase II mechanistic study in systemic sclerosis and the coming phase III study in COVID-19
Webcast presentation, Dec 21 2020
Presentation of expanded results from the phase II trial in COVID-19.
Redeye interview, Dec 11 2020
Interview with Carl-Johan Dalsgaard on COVID-19 top line data.
Webcast presentation, Dec 8 2020
Presentation of top line data from the phase II trial in COVID-19.
Stora aktiedagen, Nov 10 2020
CFO, Hans Jeppsson presented Vicore Pharma at Stora Aktiedagen in Gothenburg.
Pareto Securities Healthcare Conference, Sep 5 2020
Interview with CEO, Carl-Johan Dalsgaard during Pareto Securities Healthcare Conference.
Webcast presentations, Jun 3 2020
CEO, Carl-Johan Dalsgaard presented Vicore Pharma at Avanza digitala börsdag.
Webcast presentation, Apr 28 2020
CEO, Carl-Johan Dalsgaard presented the approved upcoming phase II study with VP01 in COVID-19.
Webcast presentation, Mar 31 2020
CEO, Carl-Johan Dalsgaard presented the planned phase II study with C21 in COVID-19.
Sitdown interview with Finwire, Dec 16 2019
Interview with CEO, Carl-Johan Dalsgaard (swedish only)